FDA Inspection 1006761 — Fresenius Kabi Austria Gmbh
The FDA completed an inspection of Fresenius Kabi Austria Gmbh on Mar 24, 2017 in Linz. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Mar 24, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Linz (Austria)